| 13.05 15:17 | dpa-AFX: AbbVie To Collaborate With Gilgamesh To Develop Next-Gen Psychiatric Therapies |
| 13.05 14:44 | dpa-AFX: *ABBVIE TO PAY GILGAMESH $65 MLN UPFRONT FOR PSYCHIATRIC THERAPIES, POTENTIAL $1.95 BLN IN OPTION FEES, AND OTHERS |
| 13.05 14:42 | dpa-AFX: *ABBVIE, GILGAMESH COLLABORATE TO DEVELOP NEXT-GENERATION THERAPIES FOR PSYCHIATRIC DISORDERS |
| 08.05 15:37 | dpa-AFX: AbbVie's Qulipta Gets Health Canada Approval For Chronic Migraine In Adults |
| 08.05 14:04 | dpa-AFX: *ABBVIE : HEALTH CANADA APPROVES QULIPTA FOR PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN ADULTS |
| 30.04 12:47 | dpa-AFX: *DZ BANK SENKT FAIREN WERT FÜR ABBVIE AUF 188 (196) USD - 'KAUFEN' |
| 30.04 12:47 | dpa-AFX: *DZ BANK CUTS FAIR VALUE FOR ABBVIE TO 188 (196) USD - 'BUY' |
| 26.04 15:07 | MÄRKTE USA/Wall Street mit günstigen Preisdaten freundlich gesehen |
| 26.04 14:07 | dpa-AFX: ROUNDUP: AbbVie Lifts FY24 Outlook After Higher Q1 Results |
| 26.04 13:45 | dpa-AFX: AbbVie Q1 Profit Increases, beats estimates |
| 26.04 13:38 | dpa-AFX: *ABBVIE Q1 NET EARNINGS ATTRIBUTABLE TO ABBVIE $1.369 BLN VS $239 MLN LAST YEAR |
| 26.04 13:37 | dpa-AFX: *ABBVIE LIFTS 2024 ADJ EPS GUIDANCE TO $11.13 - $11.33 |
| 26.04 13:37 | dpa-AFX: *ABBVIE Q1 NET REVENUES $12.31 BLN, UP 0.7% ON REPORTED BASIS AND 1.6% ON OPERATIONAL BASIS |
| 26.04 13:36 | dpa-AFX: *ABBVIE Q1 GAAP EPS $0.77; ADJ EPS $2.31 |
| 26.04 12:03 | dpa-AFX: AbbVie Q1 24 Earnings Conference Call At 9:00 AM ET |
| 25.04 16:15 | dpa-AFX: AbbVie's Rinvoq Shows Positive Results Over Dupixent In Atopic Dermatitis Study |
| 25.04 14:09 | dpa-AFX: *ABBVIE'S RINVOQ OUTPERFORMS DUPIXENT IN ATOPIC DERMATITIS STUDY |
| 18.04 15:10 | dpa-AFX: AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis |
| 18.04 14:38 | dpa-AFX: *ABBVIE'S PHASE 3 STUDY OF UPADACITINIB SHOWS POSITIVE RESULTS IN GIANT CELL ARTERITIS PATIENTS |
| 25.03 13:42 | dpa-AFX: AbbVie To Acquire Landos Biopharma At $20.42/share In Cash |
|
|
